National Bioscience Report Reveals Positive Trends for Bioscience Industry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

National Bioscience Report Reveals Positive Trends for Bioscience Industry



A recent study analyzing the US bioscience industry growth over the past 11 years, through the recent recession and early economic recovery, reveals positive trends. The industry demonstrated a strong record of growth from 2001-2012.

The report, Battelle/BIO State Bioscience Jobs, Investments and Innovation 2014, the sixth in a biennial series from Battelle and BIO tracking the US bioscience industry, reveals a strong bioscience sector on course for continued growth. The state-by-state industry assessment finds US bioscience firms directly employ 1.62 million people, a figure that includes nearly 111,000 new, high-paying jobs created since 2001.

Within the private sector, the bioscience industry has contributed an additional 6.24 million jobs through the indirect employment effect, yielding a total employment impact of 7.86 million jobs. Furthermore, the bioscience industry continues to create and sustain high-wage jobs, paying an average 80% more than the overall private sector average salary and growing at a faster rate.

The US bioscience industry handled the recession much better than the overall economy and other knowledge-based industries. While national private sector employment fell by 3.1% from the outset of the recession in 2007 through 2012, bioscienceindustry employment fell only 0.4%. Although employment has almost returned to its pre-recession level, the economic output of the bioscience industry has expanded significantly, with 17% growth since 2007, almost twice the national private sector nominal output growth.

Source: http://www.bio.org/articles/battellebio-state-bioscience-jobs-investments-and-innovation-2014

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here